The FDA does not currently require label statements regarding a product's comparative effectiveness. Dr. Randall Stafford, Todd Wagner, and Philip Lavori propose an expanded labeling requirement that would provide explicit information about proven comparative benefits or lack thereof.
No takes yet. Share an insight, caveat, or question.
Stafford et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: